Key points are not available for this paper at this time.
The GLP-1-based therapies will change the treatment of obesity and its comorbidities including steatotic liver disease in the future. Outstanding question is maintenance of the weight loss, possibly pharmacological treatment needs to be life-long.
Madsbad et al. (Sat,) studied this question.